X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - ZACKS.COM - All Stories - 10/Sep 14:41

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Articles similaires

Sorry! Image not available at this time

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

zacks.com - 10/Sep 14:41

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control...

Sorry! Image not available at this time

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

zacks.com - 04/Sep 12:32

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain...

Sorry! Image not available at this time

3D Systems Expands Orthopedic Surgical Planning Portfolio Receiving FDA Clearance for Key Ankle Indications

healthtechzone.com - 11/Sep 12:30

Sorry! Image not available at this time

THINK Surgical Receives FDA 510(k) Clearance for Zimmer Biomet Persona Knee on TMINI® Miniature Robotic System

healthtechzone.com - 05/Sep 20:00

Sorry! Image not available at this time

THINK Surgical Receives FDA 510(k) Clearance for Zimmer Biomet Persona Knee on TMINI® Miniature Robotic System

healthtechzone.com - 05/Sep 20:00

Sorry! Image not available at this time

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

zacks.com - 12/Sep 15:55

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Sorry! Image not available at this time

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

zacks.com - 12/Sep 15:55

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Sorry! Image not available at this time

Alio Launches Calibration and Validation (CAVA) Study to Expand Alio Platform's FDA Clearance Beyond the Vascular Access for Use in a Broader Range of Patients

healthtechzone.com - 12/Sep 18:02

Sorry! Image not available at this time

Alio Launches Calibration and Validation (CAVA) Study to Expand Alio Platform's FDA Clearance Beyond the Vascular Access for Use in a Broader Range of Patients

healthtechzone.com - 12/Sep 18:02

Sorry! Image not available at this time

CVS Stock Gains From Its Birth Control Prescribing Service Launch

zacks.com - 13/Sep 12:25

CVS Health announces that nearly 400 CVS Pharmacy locations in Massachusetts have started offering hormonal contraceptive prescribing services.

Les derniers communiqués